Integrated genomic profiling expands clinical options for patients with cancer
- 30 September 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Biotechnology
- Vol. 37 (11), 1351-1360
- https://doi.org/10.1038/s41587-019-0259-z
Abstract
Genomic analysis of paired tumor–normal samples and clinical data can be used to match patients to cancer therapies or clinical trials. We analyzed 500 patient samples across diverse tumor types using the Tempus xT platform by DNA-seq, RNA-seq and immunological biomarkers. The use of a tumor and germline dataset led to substantial improvements in mutation identification and a reduction in false-positive rates. RNA-seq enhanced gene fusion detection and cancer type classifications. With DNA-seq alone, 29.6% of patients matched to precision therapies supported by high levels of evidence or by well-powered studies. This proportion increased to 43.4% with the addition of RNA-seq and immunotherapy biomarker results. Combining these data with clinical criteria, 76.8% of patients were matched to at least one relevant clinical trial on the basis of biomarkers measured by the xT assay. These results indicate that extensive molecular profiling combined with clinical data identifies personalized therapies and clinical trials for a large proportion of patients with cancer and that paired tumor–normal plus transcriptome sequencing outperforms tumor-only DNA panel testing.Keywords
This publication has 62 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- The Genotype-Tissue Expression (GTEx) projectNature Genetics, 2013
- Blocking NRG1 and Other Ligand-Mediated Her4 Signaling Enhances the Magnitude and Duration of the Chemotherapeutic Response of Non–Small Cell Lung CancerScience Translational Medicine, 2013
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody CetuximabScience Translational Medicine, 2011
- Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human CancersCancer Cell, 2011
- An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer CellsCancer Cell, 2010
- ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung CancerJournal of Thoracic Oncology, 2009
- Fast and accurate short read alignment with Burrows–Wheeler transformBioinformatics, 2009
- Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate CancerScience, 2005